An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea

Sleep

Volumn 34, Issue 6, 2011, Pages 695-709

  Pietzsch, Jan B ^a,c   Garner, Abigail ^a   Cipriano, Lauren E ^c   Linehan, John H ^b  

^a Wing Tech Inc   (United States)

^b Northwestern University   (United States)

^c Stanford University   (United States)

Author keywords

Comparative effectiveness; Continuous positive airway pressure; Health economics; Markov model; Obstructive; Sleep apnea

Indexed keywords

ADULT; AGED; APNEA HYPOPNEA INDEX; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP APNEA SYNDROME;

ADULT; CONTINUOUS POSITIVE AIRWAY PRESSURE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); POLYSOMNOGRAPHY; QUALITY-ADJUSTED LIFE YEARS; SLEEP APNEA, OBSTRUCTIVE;

EID: 79957948169     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/SLEEP.1030     Document Type: Article

References (69)

1. Kapur V, Strohl KP, Redline S, Iber C, O'Connor G, Nieto J. Under-diagnosis of sleep apnea syndrome in U.S. communities. Sleep Breath 2002;6:49-54. (Pubitemid 34752698)
2. Ayas NT, FitzGerald JM, Fleetham JA, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med 2006;166:977-84.
3. Weatherly HL, Griffin SC, Mc Daid C, et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care 2009;25:26-34.
4. Sadatsafavi M, Marra CA, Ayas NT, Stradling J, Fleetham J. Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea. Sleep Breath 2009.
5. Mar J, Rueda JR, Duran-Cantolla J, Schechter C, Chilcott J. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J 2003;21:515-22. (Pubitemid 36336214)
6. Deutsch PA, Simmons MS, Wallace JM. Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome. J Clin Sleep Med 2006;2:145-53. (Pubitemid 43893264)
7. George CF. Sleep apnea, alertness, and motor vehicle crashes. Am J Respir Crit Care Med 2007;176:954-6. (Pubitemid 350127837)
8. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53. (Pubitemid 40386782)
9. Chesson AL Jr, Berry RB, Pack A. Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. Sleep 2003;26:907-13. (Pubitemid 39610640)
10. Morgenthaler TI, Aurora RN, Brown T, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep 2008;31:141-7.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
12. Fletcher EC, Stich J, Yang KL. Unattended home diagnosis and treatment of obstructive sleep apnea without polysomnography. Arch Fam Med 2000;9:168-74.
13. Arias E. United States Life Tables, 2004. National Vital Statistics Report 2007;56:1-39.
14. Center for Disease Control. Health, United States, 2008. In: U.S. Deparment of Health and Human Services NCfHS, ed. Wahington, DC: DHHS, 2009.
15. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making 1995;15:158-69.
16. British Heart Foundation Statistics Website. HeartStats. In: British Heart Foundation, 2009.
17. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-80.
18. Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MM. Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2003;74:317-21. (Pubitemid 36259354)
19. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27.
20. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161:1183-92. (Pubitemid 32691515)
21. Chang D. Comparison of crash fatalities by sex and age group. In: Analysis NCfSa, ed. Washington, DC: National Highway Traffic Safety Administration, 2008.
22. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41. (Pubitemid 41609096)
23. George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001;56:508-12. (Pubitemid 32588527)
24. Barbe F, Sunyer J, de la Pena A, et al. Effect of continuous positive airway pressure on the risk of road accidents in sleep apnea patients. Respiration 2007;74:44-9. (Pubitemid 46012446)
25. O'Connor GT, Caffo B, Newman AB, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med 2009;179:1159-64.
26. McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:1108-14. (Pubitemid 29202543)
27. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68-73. (Pubitemid 36070935)
28. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007;167:757-64.
29. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20. (Pubitemid 44050845)
30. Nyman JA, Barleen NA, Kirdruang P. Quality-adjusted life years lost from nonfatal motor vehicle accident injuries. Med Decis Making 2008;28:819-28.
31. Tousignant P, Cosio MG, Levy RD, Groome PA. Quality adjusted life years added by treatment of obstructive sleep apnea. Sleep 1994;17:52-60. (Pubitemid 24103641)
32. Chakravorty I, Cayton R, Szczepura A. Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. Eur Respir J 2002;20:1233-8. (Pubitemid 35331883)
33. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood) 2004;23:176-83.
34. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood) 2001;20:188-95. (Pubitemid 33710333)
35. Stuart B, Lloyd J, Zhao L, Kamal-Bahl S. Obesity, disease burden, and prescription spending by community-dwelling Medicare beneficiaries. Curr Med Res Opin 2008;24:2377-87.
36. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66. (Pubitemid 26295889)
37. Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006;151:206-12. (Pubitemid 41815357)
38. Qureshi AI, Suri MF, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke 2007;38:2180-4.
39. Blincoe LJ, Seay A, Zaloshnja E, et al. The Economic Impact of Motor Vehicle Crashes, 2000. In: Administration NHTS, ed. Washington, DC: U.S. Department of Transportation, 2002.
40. Littner M, Hirshkowitz M, Davila D, et al. Practice parameters for the use of auto-titrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome. An American Academy of Sleep Medicine report. Sleep 2002;25:143-7. (Pubitemid 34193576)
41. Campos-Rodriguez F, Pena-Grinan N, Reyes-Nunez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005;128:624-33. (Pubitemid 41140489)
42. McDaid C, Duree KH, Griffin SC, et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev 2009;13:427-36.
43. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending - implications for reform. N Engl J Med 2010;362:460-5.
44. Flemons WW, Douglas NJ, Kuna ST, Rodenstein DO, Wheatley J. Access to diagnosis and treatment of patients with suspected sleep apnea. Am J Respir Crit Care Med 2004;169:668-72. (Pubitemid 38338917)
45. Tan MC, Ayas NT, Mulgrew A, et al. Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea-hypopnea in British Columbia. Can Respir J 2008;15:159-65. (Pubitemid 351877373)
46. McDaid C, Griffin S, Weatherly H, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technol Assess 2009;13:iii-iv, xi-xiv, 1-119, 43-274.
47. Chervin RD, Murman DL, Malow BA, Totten V. Cost-utility of three approaches to the diagnosis of sleep apnea: polysomnography, home testing, and empirical therapy. Ann Intern Med 1999;130:496-505. (Pubitemid 29135802)
48. Epstein LJ, Dorlac GR. Cost-effectiveness analysis of nocturnal oximetry as a method of screening for sleep apnea-hypopnea syndrome. Chest 1998;113:97-103. (Pubitemid 28044931)
49. Ayas NT, Fox J, Epstein L, Ryan CF, Fleetham JA. Initial use of portable monitoring versus polysomnography to confirm obstructive sleep apnea in symptomatic patients: an economic decision model. Sleep Med 2010;11:320-4.
50. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998;80:40-4. (Pubitemid 28351117)
51. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-85.
52. Roger VL, Jacobsen SJ, Weston SA, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 2002;136:341-8.
53. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800. (Pubitemid 23163551)
54. Trikalinos TA, Lau J. Obstructive Sleep Apnea-Hypopnea Syndrome: modeling different diagnostic strategies. 2007 12/04/07 [cited 2009]; Available from: http://www.cms.hhs.gov/determinationprocess/downloads/id50TA.pdf
55. Reichert JA, Bloch DA, Cundiff E, Votteri BA. Comparison of the Nova- Som QSG, a new sleep apnea home-diagnostic system, and polysomnography. Sleep Med 2003;4:213-8. (Pubitemid 36748606)
56. Woodson BT, Steward DL, Weaver EM, Javaheri S. A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 2003;128:848-61. (Pubitemid 37339060)
57. Bae SC, Corzillius M, Kuntz KM, Liang MH. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:46-53. (Pubitemid 36131566)
58. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 2008;31:1686-96.
59. Patil CG, Long EF, Lansberg MG. Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg 2009;110:508-13.
60. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290:3101-14. (Pubitemid 37548116)
61. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-99.
62. Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. Value Health 2009;12:1-9.
63. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243-54.
64. Levesque BG, Cipriano LE, Chang SL, Lee KK, Owens DK, Garber AM. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol 2010;8:261-7, 7 e1-4.
65. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85. (Pubitemid 40204670)
66. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006;98:774-82. (Pubitemid 43983301)
67. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007;298:629-37. (Pubitemid 47236414)
68. Beinfeld MT, Wittenberg E, Gazelle GS. Cost-effectiveness of whole-body CT screening. Radiology 2005;234:415-22. (Pubitemid 40139911)
69. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 2003;228:515-22. (Pubitemid 36910096)